@article{11059,
  keywords = {Humans, *Diabetes Mellitus, Type 2/drug therapy/epidemiology/complications, *Dipeptidyl-Peptidase IV Inhibitors/adverse effects, Cohort Studies, Sulfonylurea Compounds/adverse effects, *Skin Neoplasms/chemically induced/epidemiology/complications, *Melanoma/epidemiology/complications, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Dipeptidyl Peptidase 4, Drug Effects, Medical Oncology, pharmacoepidemiology},
  author = {R. Pradhan and O. H. Y. Yu and R. Platt and L. Azoulay},
  title = {Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study},
  year = {2023},
  journal = {BMJ Open Diabetes Res Care},
  volume = {11},
  edition = {2023/11/11},
  number = {6},
  isbn = {2052-4897},
  doi = {10.1136/bmjdrc-2023-003550},
  note = {2052-4897
Pradhan, Richeek
Yu, Oriana H Y
Platt, Robert W
Azoulay, Laurent
Orcid: 0000-0001-5162-3556
FDN-143328/CIHR/Canada
Journal Article
Research Support, Non-U.S. Gov't
England
BMJ Open Diabetes Res Care. 2023 Nov;11(6):e003550. doi: 10.1136/bmjdrc-2023-003550.},
  language = {eng},
}